Skip to main content
Top
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

Discrepancies and challenge of ductal carcinoma in situfor health professionals

Authors: F Kennedy, D Harcourt, N Rumsey

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer. While debate persists about its most appropriate treatment, women diagnosed with DCIS are faced with a paradox; although they are often reassured that the condition has been caught early and is not life-threatening, they undergo similar treatments (including mastectomy) to invasive breast cancer patients [1]. Ongoing research by the authors exploring the psychosocial impact of DCIS has found that women hold diverse beliefs about the condition [2]. This work, along with previous research, suggests that DCIS patients can be confused about the condition and that the terminology used by health professionals and the treatment recommendations given to patients may enhance this misunderstanding [3]. Health professionals' attitudes about DCIS may also vary, which in turn could impact on patient care, satisfaction and risk perceptions of the condition. Previous research suggests that discrepancies between patient and health professional perceptions of invasive breast cancer can disrupt communication and compromise care [4]. Therefore, the present study aimed to explore health professionals' perceptions of DCIS, including the terminology they use with patients and the challenges the condition presents in their work. …
Literature
1.
go back to reference Webb C, Koch T: Women's experiences of non-invasive breast cancer: literature review and study report. J Adv Nurs. 1997, 25: 514-525. 10.1046/j.1365-2648.1997.t01-1-1997025514.x.CrossRefPubMed Webb C, Koch T: Women's experiences of non-invasive breast cancer: literature review and study report. J Adv Nurs. 1997, 25: 514-525. 10.1046/j.1365-2648.1997.t01-1-1997025514.x.CrossRefPubMed
2.
go back to reference Kennedy F, Harcourt D, Rumsey N: The challenge of being diagnosed and treated for ductal carcinoma in situ (DCIS). Eur J Oncol Nurs. 2007, Kennedy F, Harcourt D, Rumsey N: The challenge of being diagnosed and treated for ductal carcinoma in situ (DCIS). Eur J Oncol Nurs. 2007,
3.
go back to reference De Morgan S, Redman S, White KJ, Cakir B, Boyages J: 'Well, have I got cancer or haven't I?' The psychosocial issues for women diagnosed with ductal carcinoma in situ. Health Expect. 2002, 5: 310-318. 10.1046/j.1369-6513.2002.00199.x.CrossRefPubMedPubMedCentral De Morgan S, Redman S, White KJ, Cakir B, Boyages J: 'Well, have I got cancer or haven't I?' The psychosocial issues for women diagnosed with ductal carcinoma in situ. Health Expect. 2002, 5: 310-318. 10.1046/j.1369-6513.2002.00199.x.CrossRefPubMedPubMedCentral
4.
go back to reference Buick DL: Illness representations and breast cancer: coping with radiation and chemotherapy. Perceptions of Health and Illness: Current Research and Applications. Edited by: Petrie KJ, Weinman JA. 1997, Amsterdam: Harwood Academic Publishers, 379-409. Buick DL: Illness representations and breast cancer: coping with radiation and chemotherapy. Perceptions of Health and Illness: Current Research and Applications. Edited by: Petrie KJ, Weinman JA. 1997, Amsterdam: Harwood Academic Publishers, 379-409.
Metadata
Title
Discrepancies and challenge of ductal carcinoma in situfor health professionals
Authors
F Kennedy
D Harcourt
N Rumsey
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1968

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine